

FORM 51-102F3

MATERIAL CHANGE REPORT

ITEM 1 Name and Address of Company:

OCUMETICS TECHNOLOGY CORP. (formerly Quantum Blockchain Technologies Ltd.) (the “Corporation”)

2041 Everett Street
Abbotsford, BC V2S 7S1

ITEM 2 Date of Material Change:

October 18, 2021

ITEM 3 News Release:

The news release was distributed on October 18, 2021 and filed on SEDAR on October 19, 2021.

ITEM 4 Summary of Material Change:

The Corporation announced that it had appointed Doyle Stulting, M.D., Ph.D, as its Chief Medical Officer.

ITEM 5 Full Description of Material Change:

The Corporation announced that it had appointed Doyle Stulting, M.D., Ph.D, as its Chief Medical Officer.

“We are thrilled to have Dr. Stulting join our team,” says Dr. Mark Lee, President and CEO of Ocumetics. “As Chief Medical Officer of Ocumetics, Dr. Stulting will draw from his extensive experience to lead the company through our upcoming clinical trials. Together with Dr. Garth Webb, our Chief Scientific Officer and the inventor of the Bionic Lens, Dr. Stulting will be instrumental in the process of gaining regulatory approval of the Bionic Lens in multiple countries and bringing the Bionic Lens to full commercialization.”

Dr. Doyle Stulting is Director of the Stulting Research Center, Woolfson Eye Institute, Atlanta, GA, Professor of Ophthalmology Emeritus, Emory University, and Adjunct Professor of Ophthalmology, the Moran Eye Institute, Salt Lake City, UT.

Dr. Stulting began his career with basic research in herpetic ocular infections and corneal transplant immunology. He was Co-Director of the Collaborative Corneal Transplantation Studies, a large, NIH-supported multi-center study of histocompatibility and corneal transplantation. He then turned his attention to refractive surgery, as an investigator in a physician-sponsored clinical investigation of LASIK that was carried out before the first refractive laser was approved by the FDA in the United States. He has had a referral practice in cornea/external disease and performed routine and complex cataract surgery, as well as corneal transplantation until January 2019, when he began to specialize in the management of keratoconus. Dr. Stulting has been Principal Investigator for 5 different clinical trials for corneal crosslinking since 2008.

For ten years, Dr. Stulting was a member of the FDA Ophthalmic Devices Panel, and he completed a term as Chair of the Panel in 1998. He is Past President of the American Society for Cataract and Refractive Surgery, has served on the Board of Directors of the Eyebank Association of America, is a member of the Board of Trustees of the Georgia Eye Bank, and is Co-Medical Director of the Georgia Eye Bank. Dr. Stulting completed a 10-year term as Editor-In-Chief of the journal Cornea and remains on the Editorial Boards of other journals.

Dr. Stulting has authored over 250 papers in peer-reviewed journals, published several textbook chapters, taught courses for over 30 years at the American Academy of Ophthalmology, and lectured around the world. He was awarded the American Academy of Ophthalmology's Lifetime Achievement Award and the FDA's Citation for Excellence, Commitment, and Outstanding Service in Protecting the Public. He received the prestigious Paton Award from the Eye Bank Association of America, the Barraquer Award from the International Society of Refractive Surgery, and the Binkhorst Award from the American Society for Cataract and Refractive Surgery.

Dr. Stulting graduated summa cum laude from Duke University in Durham, N.C, with a BS degree in chemistry. He received his MD degree and PhD in microbiology and immunology from Duke. He completed his internal medicine internship and residency at Washington University's Barnes Hospital and his ophthalmology residency at the University of Miami, Bascom Palmer Eye Institute. Dr. Stulting completed a fellowship in cornea and external disease at Emory University, where he practiced, taught, and performed research from 1982 through 2010.

In 2010, he left Emory University to establish the Stulting Research Center at Woolfson Eye Institute, where he conducts a variety of clinical trials. He puts his regulatory and clinical trial experience to work as a consultant for small and large companies to bring new technologies to the market.

About Ocumetics

Ocumetrics Technology Corp. (TSXV:“OTC”) is a Canadian research and product development company that specializes in adaptive lens designs. Ocumetrics is in the pre-clinical stage of a game-changing technology for the ophthalmic industry – the Bionic Lens. The Bionic Lens is an expandable intraocular lens that fits within the natural lens compartment of the eye to completely eliminate the need for corrective lenses. It re-establishes the natural kinetics of the eye muscles to facilitate the eye’s ability to shift focus effortlessly from distance to near and very near range.

ITEM 6 **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102:**

Not Applicable.

ITEM 7 **Omitted Information:**

Not Applicable.

ITEM 8 Executive Officer:

Further information relating to this Material Change Report may be obtained from:

Mark Lee, President and Chief Executive Officer

Telephone: (604) 832-6052

ITEM 9 Date of Report:

October 19, 2021

The foregoing accurately discloses the material change referred to in this report.